Professor Demetri is Professor of Medicine at Harvard Medical School, Co-Director of the Ludwig Center at Harvard, and Associate Director for Clinical Sciences at the Dana-Farber/Harvard Cancer Center.
Professor Demetri has interests in developing rationally targeted anticancer therapeutics through fundamental research in cancers, with an emphasis on molecularly defined diseases such as GIST and other mesenchymal malignancies. Professor Demetri has served as clinical or scientific advisor to several companies including Plexxikon, G1 Therapeutics and Kolltan Pharmaceuticals, and he is a member of the Board of Directors as well as the Scientific Advisory Board of Blueprint Medicines. He received his undergraduate degree in Biochemistry from Harvard College and his Medical Degree from Stanford University School of Medicine, after which he trained in Internal Medicine with chief residency at the University of Washington Hospitals in Seattle. He is co-chair of the medical advisory board of the Sarcoma Foundation of America, and a member of the Board of Directors for the American Association for Cancer Research and the Hope Funds for Cancer Research.